Article
CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2003
Van Rijnsoever Marius, Elsaleh Hany, Joseph David, McCaul Kieran, Iacopetta Barry
Abstract excerpt
PURPOSE: The CpG island methylator phenotype (CIMP) is observed in approximately 30% of colorectal cancer (CRC) cases and is characterized by the concurrent methylation of multiple CpG islands in tumor DNA. This phenotype (CIMP+) is more frequently observed in tumors with proximal location, microsatellite instability, and normal p53. Because it has previously been observed that each of these features is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
